Bank of America Increases ProKidney (NASDAQ:PROK) Price Target to $4.00

ProKidney (NASDAQ:PROK – Get Free Report) had its price objective increased by research analysts at Bank of America from $3.00 to $4.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s price objective suggests a potential downside of 4.76% from the company’s current […]

Leave a Reply

Your email address will not be published.

Previous post Summit Financial Group (NASDAQ:SMMF) Now Covered by StockNews.com
Next post Morgan Stanley Cuts Lululemon Athletica (NASDAQ:LULU) Price Target to $404.00